MedTrace Logo

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

NCT02073916 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-04-16

No results posted yet for this study

Summary

This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.

Conditions

Interventions

DRUG

T-DM1

antibody-drug conjugate of trastuzumab and emtansine

DRUG

Lapatinib

Dual tyrosine kinase inhibitor (HER2 and EGFR)

DRUG

Abraxane

albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor

Sponsors & Collaborators

  • The Methodist Hospital Research Institute

    collaborator OTHER

  • Jenny C. Chang, MD

    lead OTHER

Principal Investigators

  • Jenny C Chang, MD · The Methodist Hospital Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02073916 on ClinicalTrials.gov